Daniel D. Long - 10 Nov 2025 Form 4 Insider Report for Septerna, Inc. (SEPN)

Role: SVP, Drug Discovery
Signature: /s/ Ran Xiao, Attorney-in-Fact
Issuer symbol: SEPN
Transactions as of: 10 Nov 2025
Net transactions value: -$63,223
Form type: 4
Filing time: 13 Nov 2025, 20:13:18 UTC
Previous filing: 11 Aug 2025
Next filing: 10 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Long Daniel D.	SVP, Drug Discovery	C/O SEPTERNA, INC., 250 EAST GRAND AVENUE, SOUTH SAN FRANCISCO	/s/ Ran Xiao, Attorney-in-Fact	13 Nov 2025	0002040349

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SEPN	Common Stock	Sale	$63,223	-3,501	-3.6%	$18.06	92,911	10 Nov 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.04 to $18.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2	Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on October 31, 2025 in transactions that were exempt under Rule 16b-3(c).

Content

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.04 to $18.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on October 31, 2025 in transactions that were exempt under Rule 16b-3(c).